進行性 心不全 の 腎臓 機能 障害 の 評価 と 治療: アメリカ 心臓 協会 の 科学 的 声明
Circulation
|September 10, 2024
まとめ
進行した心不全の早期発見は不可欠です. この記述は,心不全患者の腎臓疾患の評価,管理,および緩和ケアに関するガイドラインです.
科学分野:
- 心臓病科
- 腎臓科
- 内科 医学
背景:
- 腎臓機能障害は進行した心不全において一般的であり,患者の結果に影響を及ぼします.
- クレアチニン以外の機能障害には,液体/電解質の不均衡,尿中の溶液保持,内分泌の障害が含まれます.
- 血液動力学的変化と神経ホルモン反応は腎臓指数の変動を引き起こす可能性があります.
研究 の 目的:
- 進行性心不全における腎機能障害の評価のための枠組みを提供するためです.
- 先進的な治療法を含む心不全経路における腎疾患の管理戦略を概説する.
- 進行性心不全と腎臓疾患が併存している患者の緩和ケアと意思決定について
主な方法:
- これは現在の知識を統合した 科学的記述です
- 臨床管理と評価の枠組みに焦点を当てています.
- 外科治療や腎臓置換治療の 術前・術後・術後のケアについて
主要な成果:
- 心不全における腎機能不全の評価のための概念的枠組みを確立する.
- 進行性心不全患者の腎臓疾患の管理方法について詳しく説明します.
- 独特の緩和ケアと意思決定の検討を強調しています.
結論:
- 本質的な腎疾患の正確な評価は,治療への反応を予測する上で重要なものです.
- 心不全と腎疾患の統合管理は不可欠です.
- 緩和医療は 進行した段階で重要な役割を果たします
関連する概念動画
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


